Vazyme Biotech Co., Ltd (SHA: 688105), a biotechnology company based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for two of its respiratory syncytial virus (RSV) detection kits. The newly approved products include the RSV antigen detection kit utilizing the colloidal gold method and the RSV antigen detection kit employing quantum dot fluorescence immunoassay. Both kits are designed for the in vitro qualitative detection of RSV antigen in throat swab samples, offering auxiliary diagnostic support for RSV infections.
RSV is recognized as a prevalent pathogen responsible for lower respiratory tract infections, such as bronchiolitis and pneumonia, particularly in infants and young children under the age of one. However, it is not limited to this demographic, as older children and adults can also contract the virus, typically presenting with upper respiratory tract infections or bronchitis.- Flcube.com
